The Baddest Bug on the Ward: An Ongoing Debate
Medium: Vodcast (Online Activity with RSS Feed)
Release Date: Tuesday, December 8, 2009
Credit Expiration Date: Friday, April 29, 2011
Pharmacists CPE: 2.0 (0.2 CEUs)
This online activity is based on the proceedings of a continuing education symposium held on
December 8, 2009, during the 44th ASHP Midyear Clinical Meeting and Exhibition in Las Vegas, Nevada.
This Vodcast (audio with accompanying slides) has 3 episodes which will be released
monthly beginning February 1, 2010.
Each episode begins with a presentation of why the particular pathogen is among the most
challenging in the hospital setting. This is followed by a presentation of tactics that
clinical pharmacists can use to appropriately manage infections due to that pathogen. The
challenges associated with such infections are further discussed from the clinical, infection
control, and microbiology perspectives.
- Episode 1: MRSA
- Episode 2: ESBL/KPC-producing Enterobacteriaceae
- Episode 3: Acinetobacter and Pseudomonas
Note: If you have received credit by attending the live symposium by the same name, you
are not eligible to apply for credit for this online version.
Practice Gap and Educational Need
According to the Centers for Disease Control and Prevention, approximately two million
people develop bacterial infections in US hospitals each year, resulting in nearly 100,000
deaths. In 2004, the Infectious Diseases Society of America (IDSA) published the
call-to-action “Bad Bugs, No Drugs” that highlighted the problem of antimicrobial
resistance and the lack of new agents in development. This has since been updated
to “Bad Bugs, No ESKAPE”, where the IDSA identified the most problematic pathogens
that are able to “escape” the effects of currently available agents. These pathogens
include methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter baumannii, and
Pseudomonas aeruginosa, and ESBL-producing and KPC-producing Enterobacteriaceae.
The lack of new antimicrobial agents limits the clinicians’ ability to effectively treat
hospital-acquired infections caused by these difficult pathogens. Therefore, it is
necessary to recognize the challenges associated with each type of infection and how
to address them in the clinical setting. Positive clinical outcomes can be achieved
through continued education on appropriate use of antimicrobial agents.
This activity has been designed to meet the needs of pharmacists who are responsible for
the management of serious infections in hospitalized patients.
Those healthcare professionals participating in this knowledge-based activity will be able at its conclusion to:
- Identify the characteristics of key multidrug-resistant bacteria that cause hospital-acquired infections (HAIs).
- Implement antimicrobial dosing based on pharmacokinetic and pharmacodynamic principles to reduce resistance development.
- Proactively contribute as a key decision-maker in the management of patients with HAIs.
Richard H. Drew, PharmD, MS, BCPS
Professor, Campbell University School of Pharmacy and Health Sciences
Associate Professor of Medicine (Infectious Diseases)
Duke University School of Medicine
Durham, North Carolina
Loren G. Miller, MD, MPH
Associate Professor of Medicine,
David Geffen School of Medicine at UCLA
Division of Infectious Diseases
Director, Infection Control Program
Harbor-UCLA Medical Center
David P. Nicolau, PharmD, FCCP, FIDSA
Director, Center for Anti-Infective Research and Development
Robert P. Rapp, PharmD, FCCP
Professor of Pharmacy Emeritus, College of Pharmacy
Professor of Surgery Emeritus, College of Medicine
University of Kentucky Medical Center
George G. Zhanel, PharmD, PhD
Department of Medical Microbiology and Infectious Diseases
Faculty of Medicine
University of Manitoba
Massachusetts College of Pharmacy and Health Sciences (MCPHS) is accredited by the
Accreditation Council for Pharmacy Education as a provider for continuing pharmacy
education. Participants will receive 2.0 contact hours (0.2 CEUs) for this
activity. No partial credit will be awarded.
ACPE UAN: 0026-9999-09-083-H01-P
Activity type: Knowledge-based
For questions regarding the accreditation of this activity, please contact MCPHS
Method of Participation and Instruction for Credit
Documentation of credit will be mailed within 4 weeks of receipt of the completed Post Test, Evaluation, and
Credit Application form.
- Review the entire CE information including target audience, learning objectives, and disclosures.
- Review all three episodes in their entirety.
- Print and complete the Post Test, Evaluation, and Credit Application form.
- Mail the completed Post Test, Evaluation, and Credit Application form to Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807 or fax to (908) 235-4222.
- Post Test, Evaluation, and Credit Application Form will be available after the release of Episode 3.
- Please note that you have to receive a score of at least 70% on the Post Test to receive credit
Disclosure of Conflicts of Interest
Massachusetts College of Pharmacy and Health Sciences and Vemco MedEd require faculty, planners, and
others who are in a position to control the content of continuing education activities to disclose
to the audience any real or apparent conflict of interest related to the activity. All identified
conflicts of interest are reviewed to ensure fair balance, objectivity, and scientific rigor in
all activities. The faculty is further required to disclose discussion of off-label uses in their
Richard H. Drew, PharmD, MS, BCPS serves on the advisory boards for
Schering-Plough, Wyeth-Ayerst, and Astellas. He receives research support
from Schering-Plough and Cubist. He serves on speakers bureaus for
Schering-Plough, Wyeth-Ayerst, and Merck and is on the development Team for CustomID.
Loren G. Miller, MD, MPH is a consultant for Theravance and receives
research/grant support from Pfizer and Cubist.
David P. Nicolau, PharmD, FCCP, FIDSA serves on the advisory boards and is a
consultant for AstraZeneca, Cubist, Wyeth, Pfizer, Ortho-McNeil, and Merck. He
receives grant/research support, has intellectual property/patents and serves on
speakers bureaus for AstraZeneca, Ortho-McNeil, Cubist, Wyeth, Merck, and Pfizer.
Robert P. Rapp, PharmD, FCCP serves on the advisory boards for
Pfizer, Ortho-McNeil, and Astellas. He serves on the speakers
bureaus for Pfizer, Ortho-McNeil, and Astellas.
George G. Zhanel, PharmD, PhD serves on the advisory boards for
Merck, Ortho-McNeil, and Wyeth. He receives research/grant support
from Abbott, Affinium, Astellas, Wyeth, Pfizer, TaiGen, Ortho-McNeil,
Bayer, Sepracor, and Advanced Life Sciences.
Planning Committee Members
Employees of Vemco MedEd and Massachusetts College of Pharmacy and Health
Sciences have no relevant financial relationships to disclose.
Disclosure Off-label Use
The following off-label uses of antimicrobial agents will be discussed during
this activity: dalbavancin, oritavancin, iclaprim, ceftobiprole and ceftaroline
for the treatment of MRSA infections; tigecycline for the treatment of
hospital-acquired pneumonia and A. baumannii infections; telavancin for the
treatment of hospital-acquired pneumonia; meropenem for the treatment of cystic
fibrosis and administered via a 3-hour infusion; doripenem for the treatment of
nosocomial pneumonia and cystic fibrosis.
This activity is jointly sponsored by Massachusetts College of Pharmacy and Health Sciences and Vemco MedEd.
This activity is supported by an educational grant from Ortho-McNeil, Inc., administered by
Ortho-McNeil Janssen Scientific Affairs, LLC.
There is no fee to participate in this educational activity.
Internet Explorer or Mozilla
Note: Please disable any “pop-up blocker” features.
Flash Player to view the presentations
Adobe Acrobat Reader version 4 or above to view PDF files (If you do not have Acrobat Reader, you can download it
for free from http://get.adobe.com/reader)
Cable, DSL, or better of at least 300 kbps
PC or Apple to view the presentations
Please e-mail any questions or concerns to firstname.lastname@example.org.
Copyright © 2010 Vemco MedEd, LLC. All Rights Reserved. Permission for accreditation use
granted to Massachusetts College of Pharmacy and Health Sciences.
The opinions expressed in this educational activity are those of the faculty and do not reflect
the views of Massachusetts College of Pharmacy and Health Sciences and Vemco MedEd. This
educational activity may discuss off-label and/or investigational uses and dosages for
therapeutic products/procedures that have not been approved by the United States Food and
Drug Administration (FDA). Massachusetts College of Pharmacy and Health Sciences and Vemco
MedEd do not recommend the use of any product/procedure outside of the labeled indications. A
qualified healthcare professional should be consulted before using any therapeutic product/procedure
discussed. Learners should verify all information and data before treating patients or employing
any therapies described in this continuing education activity. Please refer to the official
prescribing information for each product/procedure for approved indication, contraindications, and warnings.
For questions regarding the accreditation of this activity, please contact MCPHS
Please note that you can participate in this activity in three ways:
- Subscribe to RSS feed
- View each episode on this website
- Through your mobile device; go to http://www.vemcomeded.mobi
By clicking on Episode 1, I acknowledge that I have read the entire CPE information.
By clicking on Episode 2, I acknowledge that I have read the entire CPE information.
By clicking on Episode 3, I acknowledge that I have read the entire CPE information.